Why is Riddhi Siddhi Gluco Biols Ltd falling/rising?

Strong Short-Term Price Momentum Amid Market Volatility

The stock’s sharp rise on 16 Jan reflects a robust short-term momentum, with a consecutive two-day gain accumulating to a 14.02% return. It opened with a gap-up of 3.96% and reached an intraday high of ₹490, representing a 14.22% increase from the previous close. This price action indicates strong buying interest at the start of the trading session, although the weighted average price suggests that a larger volume of shares traded closer to the day’s lower price levels. The stock also experienced high intraday volatility of 5.38%, signalling active trading and fluctuating investor sentiment throughout the day.

Despite this volatility, the stock outperformed its sector by 13.62% on the day, highlighting a relative strength that investors found compelling. The price remains above its 5-day, 20-day, and 50-day moving averages, which often signals positive short-term technical momentum. However, it is still trading below its 100-day and 200-day moving averages, indicating that longer-term trends have yet to fully align with the recent rally.

Contrasting Long-Term Fundamentals and Recent Financial Performance

While the stock’s recent price action is encouraging, the company’s fundamental backdrop remains weak. Over the past five years, Riddhi Siddhi Gluco Biols Ltd has experienced a negative compound annual growth rate (CAGR) of -14.03% in net sales, signalling a contraction in its core business. The firm’s ability to service debt is also concerning, with an average EBIT to interest ratio of -1.18, reflecting operational losses and insufficient earnings to cover interest expenses.

The company has reported losses for three consecutive quarters, with the latest six-month profit after tax (PAT) declining by 40.98% to ₹24.29 crore. Quarterly net sales have fallen sharply by 34.36% to ₹32.10 crore, while profit before tax excluding other income (PBT less OI) plunged by 225% to a negative ₹4.05 crore. These figures underscore ongoing operational challenges and deteriorating profitability.

Moreover, the stock’s negative return of -19.02% over the past year contrasts starkly with the Sensex’s positive 8.47% gain, highlighting underperformance relative to the broader market. The company’s negative return on capital employed (ROCE) and negative EBITDA further emphasise the financial risks investors face. Falling investor participation is evident from a steep 84.04% drop in delivery volume on 14 Jan compared to the five-day average, suggesting cautious sentiment despite the recent price rally.

Risk Considerations and Market Positioning

Riddhi Siddhi Gluco Biols Ltd’s stock is considered risky due to its weak fundamentals and volatile price behaviour. Although it has outperformed the Sensex and its sector in the short term, the company’s long-term financial health remains fragile. The stock’s liquidity is adequate for trading, but the wide intraday price range of ₹50 and high volatility indicate that investors should approach with caution.

In summary, the recent surge in Riddhi Siddhi Gluco Biols Ltd’s share price on 16 Jan is primarily driven by short-term technical factors and market momentum rather than an improvement in the company’s underlying financial performance. Investors should weigh the current price strength against the backdrop of persistent losses, declining sales, and weak debt servicing capacity before making investment decisions.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →